دورية أكاديمية
أعرض في EDS

Intranasal Liposomal Formulation of Spike Protein Adjuvanted with CpG Protects and Boosts Heterologous Immunity of hACE2 Transgenic Mice to SARS-CoV-2 Infection.

التفاصيل البيبلوغرافية
العنوان: Intranasal Liposomal Formulation of Spike Protein Adjuvanted with CpG Protects and Boosts Heterologous Immunity of hACE2 Transgenic Mice to SARS-CoV-2 Infection.
المؤلفون: Russo M; Department of Immunology, Institute of Biomedical Science, University of São Paulo (ICB-USP), São Paulo 05508-000, Brazil., Mendes-Corrêa MC; Laboratório de Virologia (LIM52), Instituto de Medicina Tropical de São Paulo, Faculdade de Medicina da Universidade de São Paulo (FM-USP), São Paulo 05403-000, Brazil., Lins BB; Department of Immunology, Institute of Biomedical Science, University of São Paulo (ICB-USP), São Paulo 05508-000, Brazil., Kersten V; Department of Immunology, Institute of Biomedical Science, University of São Paulo (ICB-USP), São Paulo 05508-000, Brazil., Pernambuco Filho PCA; Department of Immunology, Institute of Biomedical Science, University of São Paulo (ICB-USP), São Paulo 05508-000, Brazil., Martins TR; Laboratório de Virologia (LIM52), Instituto de Medicina Tropical de São Paulo, Faculdade de Medicina da Universidade de São Paulo (FM-USP), São Paulo 05403-000, Brazil.; Faculdade de Ciências Farmacêuticas, Universidade Federal do Amazonas (UFAM), Manaus 69080-900, Brazil., Tozetto-Mendoza TR; Laboratório de Virologia (LIM52), Instituto de Medicina Tropical de São Paulo, Faculdade de Medicina da Universidade de São Paulo (FM-USP), São Paulo 05403-000, Brazil., Vilas Boas LS; Laboratório de Virologia (LIM52), Instituto de Medicina Tropical de São Paulo, Faculdade de Medicina da Universidade de São Paulo (FM-USP), São Paulo 05403-000, Brazil., Gomes BM; Department of Immunology, Institute of Biomedical Science, University of São Paulo (ICB-USP), São Paulo 05508-000, Brazil., Dati LMM; Departamento de Analises Clinicas e Toxicologicas, Faculdade de Ciências Farmacêuticas da Universidade de Sao Paulo (FCF-USP), São Paulo 05508-000, Brazil., Duarte-Neto AN; Departamento de Patologia, Faculdade de Medicina da Universidade de São Paulo (FM-USP), São Paulo 05403-000, Brazil., Reigado GR; Laboratório de Biotecnologia, Escola de Artes, Ciências e Humanidades, Universidade de São Paulo (EACH-USP), São Paulo 03828-000, Brazil., Frederico ABT; Immunological Technology Laboratory, Institute of Immunobiological Technology (Bio-Manguinhos), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-900, Brazil., de Brito E Cunha DRA; Immunological Technology Laboratory, Institute of Immunobiological Technology (Bio-Manguinhos), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-900, Brazil., de Paula AV; Laboratório de Virologia (LIM52), Instituto de Medicina Tropical de São Paulo, Faculdade de Medicina da Universidade de São Paulo (FM-USP), São Paulo 05403-000, Brazil., da Silva JIG; Programa de Biologia Celular e do Desenvolvimento, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil., Vasconcelos CFM; Programa de Biologia Celular e do Desenvolvimento, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil., Chambergo FS; Laboratório de Biotecnologia, Escola de Artes, Ciências e Humanidades, Universidade de São Paulo (EACH-USP), São Paulo 03828-000, Brazil., Nunes VA; Laboratório de Biotecnologia, Escola de Artes, Ciências e Humanidades, Universidade de São Paulo (EACH-USP), São Paulo 03828-000, Brazil., Ano Bom APD; Immunological Technology Laboratory, Institute of Immunobiological Technology (Bio-Manguinhos), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-900, Brazil., Castilho LR; Cell Culture Engineering Laboratory, COPPE, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-598, Brazil., Martins RAP; Programa de Biologia Celular e do Desenvolvimento, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil., Hirata MH; Departamento de Analises Clinicas e Toxicologicas, Faculdade de Ciências Farmacêuticas da Universidade de Sao Paulo (FCF-USP), São Paulo 05508-000, Brazil., Mirotti L; Institute of Science and Technology in Biomodels (ICTB), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-900, Brazil.
المصدر: Vaccines [Vaccines (Basel)] 2023 Nov 20; Vol. 11 (11). Date of Electronic Publication: 2023 Nov 20.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG
مستخلص: Mucosal vaccination appears to be suitable to protect against SARS-CoV-2 infection. In this study, we tested an intranasal mucosal vaccine candidate for COVID-19 that consisted of a cationic liposome containing a trimeric SARS-CoV-2 spike protein and CpG-ODNs, a Toll-like receptor 9 agonist, as an adjuvant. In vitro and in vivo experiments indicated the absence of toxicity following the intranasal administration of this vaccine formulation. First, we found that subcutaneous or intranasal vaccination protected hACE-2 transgenic mice from infection with the wild-type (Wuhan) SARS-CoV-2 strain, as shown by weight loss and mortality indicators. However, when compared with subcutaneous administration, the intranasal route was more effective in the pulmonary clearance of the virus and induced higher neutralizing antibodies and anti-S IgA titers. In addition, the intranasal vaccination afforded protection against gamma, delta, and omicron virus variants of concern. Furthermore, the intranasal vaccine formulation was superior to intramuscular vaccination with a recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 spike glycoprotein (Oxford/AstraZeneca) in terms of virus lung clearance and production of neutralizing antibodies in serum and bronchial alveolar lavage (BAL). Finally, the intranasal liposomal formulation boosted heterologous immunity induced by previous intramuscular vaccination with the Oxford/AstraZeneca vaccine, which was more robust than homologous immunity.
References: Cell Rep. 2021 Jul 27;36(4):109452. (PMID: 34289385)
Viruses. 2022 Sep 29;14(10):. (PMID: 36298703)
Sci Transl Med. 2021 Jan 20;13(577):. (PMID: 33288662)
J Immunol. 2017 Jul 1;199(1):9-16. (PMID: 28630108)
J Exp Med. 2022 Oct 3;219(10):. (PMID: 36006380)
J Virol. 2007 Jan;81(2):813-21. (PMID: 17079315)
Eur J Immunol. 2004 Jan;34(1):251-62. (PMID: 14971051)
Clinics (Sao Paulo). 2022 Jun 16;77:100068. (PMID: 35767900)
Science. 2021 Jul 9;373(6551):165-167. (PMID: 34244402)
Virol J. 2018 Dec 27;15(1):192. (PMID: 30587193)
Clin Chem. 2020 Apr 1;66(4):549-555. (PMID: 32031583)
Annu Rev Immunol. 2021 Apr 26;39:695-718. (PMID: 33646857)
Science. 2020 Mar 13;367(6483):1260-1263. (PMID: 32075877)
Scand J Immunol. 2009 Dec;70(6):505-15. (PMID: 19906191)
Rev Infect Dis. 1984 May-Jun;6 Suppl 2:S361-8. (PMID: 6740074)
Viruses. 2023 May 29;15(6):. (PMID: 37376568)
Euro Surveill. 2020 Jan;25(3):. (PMID: 31992387)
J Med Virol. 2022 Dec;94(12):5678-5690. (PMID: 35902378)
Transfusion. 2020 Dec;60(12):2938-2951. (PMID: 32935877)
Euro Surveill. 2021 Oct;26(41):. (PMID: 34651577)
N Engl J Med. 2021 Dec 9;385(24):e84. (PMID: 34614326)
Nat Commun. 2022 Aug 17;13(1):4831. (PMID: 35977933)
Immunity. 2021 Dec 14;54(12):2877-2892.e7. (PMID: 34852217)
Immunity. 2010 Jul 23;33(1):71-83. (PMID: 20643338)
Sci Immunol. 2021 Oct 15;6(64):eabl4509. (PMID: 34623900)
Biotechnol Appl Biochem. 2022 Dec;69(6):2673-2685. (PMID: 35092091)
Front Immunol. 2020 Apr 23;11:692. (PMID: 32391011)
Biochem Eng J. 2022 Aug;186:108537. (PMID: 35874089)
mBio. 2020 Mar 10;11(2):. (PMID: 32156809)
Eur J Immunol. 2003 Jun;33(6):1633-41. (PMID: 12778481)
Nature. 2020 Jul;583(7818):830-833. (PMID: 32380511)
Methods Mol Biol. 2017;1601:1-17. (PMID: 28470513)
J Gen Virol. 2006 Mar;87(Pt 3):641-650. (PMID: 16476986)
Crit Care Res Pract. 2010;2010:. (PMID: 20948883)
Transfusion. 2021 Apr;61(4):1181-1190. (PMID: 33491194)
Nature. 2022 Mar;603(7902):687-692. (PMID: 35062015)
Vaccines (Basel). 2022 Aug 12;10(8):. (PMID: 36016193)
NPJ Vaccines. 2023 May 13;8(1):68. (PMID: 37179389)
Vaccines (Basel). 2022 Mar 24;10(4):. (PMID: 35455253)
Virology. 2020 Dec;551:1-9. (PMID: 33010669)
Cell. 2022 Mar 3;185(5):896-915.e19. (PMID: 35180381)
Front Immunol. 2017 Feb 03;8:47. (PMID: 28220116)
معلومات مُعتمدة: INOVA VPPCB-005-FIO-20-2-54 Programa Inova Fiocruz; 39540021 Verba parlamentar Davi Miranda; 2021.1.10424.1.9 PIPAE-USP-2021; E-26/211.711/2021 to R.A.P.M. Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro; (FAPESP) 2021/12502-7 São Paulo Research Foundation; 2021 (to R.A.P.M.) International Retinal Research Foundation/2021 (to R.A.P.M.)
فهرسة مساهمة: Keywords: CpG-ODNs; SARS-CoV-2; cationic liposome; hACE2 transgenic mice; heterologous immunity; intranasal route; spike protein; vaccine
تواريخ الأحداث: Date Created: 20231125 Latest Revision: 20231127
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10675295
DOI: 10.3390/vaccines11111732
PMID: 38006064
قاعدة البيانات: MEDLINE
الوصف
تدمد:2076-393X
DOI:10.3390/vaccines11111732